Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
15:46:38 EDT Tue 25 Mar 2025
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:OTLK - OUTLOOK THERAPEUTICS INC - https://outlooktherapeutics.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
OTLK - Q0.81.40·1.410.11.405-0.09-6.0372.54511,2341.48  1.485  1.3612.8499  0.8715:28:00Feb 2815 min RT 2¢

Recent Trades - Last 10 of 1234
Time ETExPriceChangeVolume
15:28:00Q1.41-0.085100
15:28:00Q1.405-0.09100
15:23:36Q1.405-0.0932
15:23:05Q1.405-0.0932
15:22:59Q1.41-0.085100
15:22:35Q1.405-0.0955
15:22:34Q1.405-0.0933
15:21:35Q1.405-0.0962
15:21:04Q1.405-0.0941
15:21:00Q1.41-0.08549

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-02-28 08:05U:OTLKNews ReleaseOutlook Therapeutics(TM) Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration
2025-02-19 09:00U:OTLKNews ReleaseOutlook Therapeutics(TM) Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference
2025-02-14 08:05U:OTLKNews ReleaseOutlook Therapeutics(TM) Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update
2025-02-04 09:05U:OTLKNews ReleaseOutlook Therapeutics(TM) Participates in Virtual Investor "What This Means" Segment
2025-01-31 08:05U:OTLKNews ReleaseOutlook Therapeutics(TM) Appoints Faisal G. Sukhtian as Chairman of the Board of Directors
2025-01-23 09:05U:OTLKNews ReleaseOutlook Therapeutics(TM) Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD
2025-01-22 09:05U:OTLKNews ReleaseOutlook Therapeutics(TM) to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar
2025-01-16 06:00U:OTLKNews ReleaseOutlook Therapeutics(TM) Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial
2025-01-08 09:15U:OTLKNews ReleaseOutlook Therapeutics(TM) Participates in Virtual Investor "What This Means" Segment
2024-12-27 08:05U:OTLKNews ReleaseOutlook Therapeutics(TM) Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update
2024-12-13 16:30U:OTLKNews ReleaseOutlook Therapeutics(TM) Streamlines Operations
2024-12-04 08:05U:OTLKNews ReleaseOutlook Therapeutics(TM) Announces NICE Recommendation of LYTENAVA(TM) (bevacizumab gamma) for the Treatment of Wet AMD
2024-12-03 16:30U:OTLKNews ReleaseOutlook Therapeutics(TM) Announces Executive Leadership Transition
2024-11-27 06:50U:OTLKNews ReleaseOutlook Therapeutics(TM) Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial
2024-11-06 08:05U:OTLKNews ReleaseOutlook Therapeutics(TM) to Present at the Guggenheim Healthcare Innovation Conference
2024-10-17 09:00U:OTLKNews ReleaseOutlook Therapeutics(TM) Participates in a Virtual Investor CEO Connect Segment
2024-09-16 08:05U:OTLKNews ReleaseOutlook Therapeutics(TM) to Participate in the Virtual Investor Closing Bell Series
2024-09-13 09:05U:OTLKNews ReleaseOutlook Therapeutics(TM) Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series
2024-09-04 08:35U:OTLKNews ReleaseOutlook Therapeutics(TM) Announces Completion of Enrollment in NORSE EIGHT Clinical Trial
2024-09-03 08:45U:OTLKNews ReleaseOutlook Therapeutics(TM) to Present at the H.C. Wainwright 26th Annual Global Investment Conference